Pediatric and Adolescent Solid Tumor Steering Committee
The Pediatric and Adolescent Solid Tumor Steering Committee (PASTSC) was established in 2011. PASTSC members include representatives from the Children's Oncology Group, pediatric and medical oncologists and other specialists, translational scientists, biostatisticians, patient advocates, and NCI staff.
The PASTSC works to promote the best clinical and translational science in the study of the extracranial solid tumors of children and youth by critically reviewing submitted phase 2 and phase 3 concepts for their rationale, design and priority. Concepts in brain and other central nervous system tumors are reviewed by the Brain Malignancies Steering Committee.
Clinical Trials Planning Meetings (CTPMs)
- Neuroblastoma – April 2012
- Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma (May 6, 2014)
- Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study (J Clin Oncol)
The following are clinical trials that were approved at the concept stage by the Steering Committee:
|Trial ID||NCT ID||Trial Title|
|COG-ANBL1221||NCT01767194||Phase II Randomized Trial of Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma|
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-risk Neuroblastoma
A Feasibility Study of Ifosfamide and Doxorubicin (ID) and Radiotherapy with or without Pazopanib in Patients with Newly Diagnosed Unresected Intermediate- or High-Risk Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Randomized Phase II Selection Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody AMG 479 to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Response and Biology-Based Therapy for Patients with Non-High-Risk Neuroblastoma
A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma
Phase II Study of Eribulin in Recurrent or Refractory Osteosarcoma
Phase II Study of Denosumab, a RANK Ligand Antibody, for Recurrent Osteosarcoma
Phase II Trial of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody (ch14.18) in Combination with GM-CSF in Patients with Recurrent Osteosarcoma
CCCT Contact: Wolf Lindwasser, Ph.D.